The ARIAD Board of Directors is a team of experienced, respected business leaders, committed to the highest standards of corporate governance, sound business practices and financial transparency.
Alexander J. Denner, Ph.D., is our Chairman of the Board and has been a member since February 2014. Dr. Denner is the chief investment officer and a founding partner of Sarissa Capital Management LP.
From 2006 to 2011, Dr. Denner served as Senior Managing Director of entities at Icahn Capital. From April 2005 to May 2006, Dr. Denner served as a portfolio manager specializing in healthcare investments for Viking Global Investors.
Previously, he held a variety of roles at Morgan Stanley, beginning in 1996, including as portfolio manager of healthcare and biotechnology mutual funds.
Dr. Denner received his S.B. degree from the Massachusetts Institute of Technology and his M.S., M.Phil., and Ph.D. degrees from Yale University. In addition, he served as a director of Amylin Pharmaceuticals, Inc., ImClone Systems Incorporated, Enzon Pharmaceuticals, Inc., and Mast Therapeutics, Inc. He is currently also a director at Biogen Idec and VIVUS.
Jay R. LaMarche, one of our Directors since January 1992, is a retired financial executive. Previously, he served as our Chief Financial Officer and Treasurer from January 1992 to November 2000 and as our Executive Vice President from March 1997 to November 2000. Mr. LaMarche was our Senior Vice President, Finance from January 1992 to February 1997.
Prior to joining us, he was Chief Financial Officer and a Director of ChemDesign Corporation, a fine chemicals manufacturer. Previously, Mr. LaMarche was a partner with Deloitte Haskins & Sells, a public accounting firm.
Mr. LaMarche received his B.B.A. degree in Public Accountancy from the University of Notre Dame and served as an officer in the United States Navy.
Athanase Lavidas, Ph.D., one of our directors since September 2003, is the Chairman and Chief Executive Officer of the Lavipharm Group, a pharmaceutical, cosmetics and consumer health products company in Greece, a position he has held since 1976. Dr. Lavidas is also Chairman of the Greece-U.S. Business Council and Vice Chairman of the Hellenic Federation of Enterprises, Head of International Affairs.
He received his B.S. and M.S. from the University of Munich, his M.B.A from the Institut Superieur de Marketing et de Management in Paris, and his Ph.D. degree from the University of Athens.
Paris Panayiotopoulos joined ARIAD in January 2016 as the Company’s President and Chief Executive Officer and member of its Board of Directors.
Mr. Panayiotopoulos comes to ARIAD from EMD Serono, Inc., where he most recently served as President, having joined its parent company Merck KGaA, Darmstadt, Germany in 2004. During his 11-year tenure there, Mr. Panayiotopoulos held positions of increasing responsibility. In addition to President of EMD Serono Inc, he also served as President of Merck Serono, Tokyo, Japan; Global Chief of Staff for the CEO in Geneva, Switzerland; Head of Western Europe for the Fertility and Endocrinology franchises; Global Director of the Neurology franchise; and Global Strategy and Business Intelligence Director.
Prior to joining Merck KGaA, Darmstadt, Germany, Mr. Panayiotopoulos was at Eli Lilly & Co. from 1999 to 2004.
Mr. Panayiotopoulos holds a combined BSc degree in Chemistry and Management Studies from University College London and an MSc degree in Marketing and Product Management from Cranfield Business School in the UK.
Anna Protopapas joined the ARIAD Board of Directors in April 2015. Ms. Protopapas is Chief Executive Officer of Mersana Therapeutics, a privately held, pre-clinical stage company that is focused on an anti-body drug conjugates platform that can be applied to targets in various therapeutic areas.
Ms. Protopapas previously served as a member of the Executive Committee of Takeda Pharmaceutical Company Limited from October 2010 to October 2014 and in various senior management positions at the company. Specifically, from April 2013 to October 2014, she served as the President of Millennium Pharmaceuticals, where she was responsible for leading Takeda’s oncology business. Within that period, she also held the role of Executive VP of Global Business Development of Takeda where she was responsible for global acquisitions, partnering, licensing and venture investing. From October 1997 to October 2010, Ms. Protopapas served in various positions at Millennium Pharmaceuticals as the Senior Vice President of Strategy and Business Development and a member of the Executive Committee, where she led the company’s business development initiatives.
Ms. Protopapas received a B.S. in engineering from Princeton University, an M.S. in chemical engineering practice from Massachusetts Institute of Technology and a MBA from Stanford Graduate School of Business.
Massimo Radaelli, Ph.D., one of our directors since October 2008, is the Chairman and Chief Executive Officer of Bioakos Pharma, a specialty pharmaceutical company based in Florence, Italy focused in the areas of oncology, dermatology and gynecology.
Prior to joining Bioakos in May 2009, Dr. Radaelli was President and Chief Executive Officer of Dompé International SA, the international pharmaceutical company of the Dompé Group, where he was responsible for the company’s global sales and export activities. He joined Dompé in 1996 as director of corporate business development and was responsible for the initiation of Dompé’s global strategy in its Swiss subsidiary and for its strategic planning, licensing, alliances and new-product opportunities in Europe. Previously, Dr. Radaelli held various sales and marketing positions at the Dupont-Merck Pharmaceutical Company from 1990 to 1996, the Menarini Group from 1989 to 1990 and Hoffman-La Roche Ltd. from 1982 to 1989.
Dr. Radaelli received a University Degree in pharmaceutical sciences and a Ph.D. in clinical pharmacology from the University of Milan and an Executive Master of Business from Bocconi University of Milan.
Norbert G. Riedel, Ph.D., one of our Directors since April 2011, has nearly twenty years of global pharmaceutical research, development and commercial experience. In January 2014, he was named president and chief executive officer of Naurex, Inc., a biopharmaceutical company developing therapies to treat diseases of the central nervous system based on the company's proprietary platform for discovering novel compounds that act at the NMDA receptor to modulate neuronal plasticity. In early January 2013, Dr. Riedel retired from Baxter International Inc., a diversified healthcare company, where he served as Corporate Vice President and Chief Scientific Officer since March 2001. Before assuming this role, from 1998 to 2001, Dr. Riedel served as President and General Manager of the recombinant therapeutic proteins business unit and Vice President of Research and Development at Baxter's BioScience business.
Prior to joining Baxter, from 1996 to 1998, he was head of worldwide biotechnology and worldwide core research functions at Hoechst-Marion Roussel, now Sanofi-Aventis. Previously, he held a series of scientific management positions at Hoechst-Marion Roussel and Hoechst AG. Dr. Riedel has been a member of the Supervisory Board of MediGene, AG, a biotechnology company, since 2003.
He is a member of the Board of Directors of the Illinois Biotechnology Industry Organization and also serves on the Advisory Board of Northwestern University's Kellogg School of Management Center for Biotechnology, and the McCormick School of Engineering. Most recently, he was appointed by Illinois Governor Pat Quinn to the newly formed Illinois Innovation Council.
Dr. Riedel received his diploma in biochemistry from the University of Frankfurt in 1981 and his Ph.D. in biochemistry from the University of Frankfurt in 1983.
Sarah J. Schlesinger, M.D., joined the ARIAD Board of Directors in July 2013. Dr. Schlesinger is a prominent clinical investigator and immunologist at The Rockefeller University in New York City who has spent more than 20 years working in the field of cellular immunity, including as clinical director of the laboratory led by the late Ralph M. Steinman, M.D., 2011 Nobel Laureate in Physiology or Medicine. She is currently Senior Attending Physician and Associate Professor of Clinical Investigation at the Laboratory of Cellular Physiology and Immunology at Rockefeller. Prior to joining the University, Dr. Schlesinger was a scientist at the International AIDS Vaccine Initiative in New York City. From 1996 to 2002, Dr. Schlesinger was a Research Physician/Pathologist at the Division of Retrovirology at Walter Reed Army Institute of Research, having previously served, from 1994 to 2002, as Staff Pathologist at the Armed Force Institute of Pathology in Washington, DC. Dr. Schlesinger trained in Surgery at the Albert Einstein College of Medicine and began her career in pathology at Georgetown University in Washington, DC, and hospitals in New York including Buffalo General, Hospital New York and the Manhattan Eye, Ear and Throat Hospital.
Dr. Schlesinger leads clinical trials and also chairs the research education and training committee of the Center for Clinical and Translational Science at The Rockefeller University Hospital. She is co-director of the University’s Clinical Scholars program, the Certificate in Clinical and Translational Sciences program and is the vice-chair of the hospital’s Institutional Review Board. Widely published in her field, Dr. Schlesinger has been recognized with numerous awards for her research and teaching. She also belongs to a number of prominent medical societies including the United States and Canadian Academy of Pathology, the American Association for the Advancement of Science and the College of American Pathologists.
Dr. Schlesinger received her bachelor’s degree from Wellesley College in Wellesley, MA, and her M.D. from Rush Medical College in Chicago.
Wayne Wilson has been a member of the Board since October 2008. He is an independent business advisor and certified public accountant. From 1995 to 2002, he served in various roles as President, Chief Operating Officer and Chief Financial Officer of PC Connection, Inc., a Fortune 1000 direct marketer of information technology products and services. Previously, Mr. Wilson was a partner in the assurance and advisory services practice of Deloitte & Touche LLP from 1986 to 1995.
Mr. Wilson received an A.B. degree in political science from Duke University and an M.B.A. with concentration in accounting and finance from the University of North Carolina at Chapel Hill.